Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 3/2020

Open Access 01-03-2020 | Esophagus Resection | Original Scientific Report

Long-Term Quality of Life After Total Gastrectomy Versus Ivor Lewis Esophagectomy

Authors: E. Jezerskyte, L. M. Saadeh, E. R. C. Hagens, M. A. G. Sprangers, L. Noteboom, H. W. M. van Laarhoven, W. J. Eshuis, M. I. van Berge Henegouwen, S. S. Gisbertz

Published in: World Journal of Surgery | Issue 3/2020

Login to get access

Abstract

Background

There is scarce evidence on whether a total gastrectomy or an Ivor Lewis esophagectomy is preferred for gastroesophageal junction (GEJ) cancers regarding effects on morbidity, pathology, survival and health-related quality of life (HR-QoL). The aim of this study was to investigate the difference in long-term HR-QoL in patients undergoing total gastrectomy versus Ivor Lewis esophagectomy in a tertiary referral center.

Methods

Patients with a follow-up of >1 year after a total gastrectomy or an Ivor Lewis esophagectomy for GEJ/cardia carcinoma completed the EORTC QLQ-C30 and EORTC QLQ-OG25 questionnaires. ‘Problems with eating,’ ‘reflux,’ and ‘nausea and vomiting’ were the primary HR-QoL endpoints. The secondary endpoints were the remaining HR-QoL domains, postoperative complications and pathology results.

Results

Thirty patients after gastrectomy and 71 after esophagectomy were included. Mean age was 63 years. Median follow-up was 2 years (range 12–84 months). Patients after gastrectomy reported less ‘choking when swallowing’ and ‘coughing’ (β = − 5.952, 95% CI − 9.437 to − 2.466; β = − 13.084, 95% CI − 18.525 to − 7.643). More lymph nodes were resected in esophagectomy group (p = 0.008). No difference was found in number of positive lymph nodes, R0 resection or postoperative complications.

Conclusions

After a follow-up of >1 year ‘choking when swallowing’ and ‘coughing’ were less common after a total gastrectomy. No differences were found in postoperative complications or radicality of surgery. Based on this study, no general preference can be given to either of the procedures for GEJ cancer. These results support shared decision making when a choice between the two treatment options is possible.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRef
2.
3.
Busweiler LA, Henneman D, Dikken JL, Fiocco M, van Berge Henegouwen MI, Wijnhoven BP, van Hillegersberg R, Rosman C, Wouters MW, van Sandick JW, D.U.G.C.A. group (2017) Failure-to-rescue in patients undergoing surgery for esophageal or gastric cancer. Eur J Surg Oncol 43(10):1962–1969CrossRef
4.
5.
Sauvanet A, Mariette C, Thomas P, Lozac’h P, Segol P, Tiret E, Delpero JR, Collet D, Leborgne J, Pradère B, Bourgeon A, Triboulet JP (2005) Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors. J Am Coll Surg 201(2):253–262CrossRef
6.
Karl RC, Schreiber R, Boulware D, Baker S, Coppola D (2000) Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg 231(5):635–643CrossRef
7.
Spector NM, Hicks F, Pickleman J (2002) Quality of life and symptoms after surgery for gastroesophageal cancer: a pilot study. Gastroenterol Nurs 25:120e5CrossRef
8.
Barbour AP, Lagergren P, Hughes R, Alderson D, Barham CP, Blazeby JM (2008) Health-related quality of life among patients with adenocarcinoma of the gastro-oesophageal junction treated by gastrectomy or oesophagectomy. Br J Surg 95:80e4CrossRef
9.
Fuchs H, Hölscher A, Leers J, Bludau M, Brinkmann S, Schröder W, Alakus H, Mönig S, Gutschow CA (2016) Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy? Gastric Cancer 19(1):312–317CrossRef
10.
Kauppila JH, Ringborg C, Johar A, Lagergren J, Lagergren P (2018) Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma. Gastric Cancer 21(3):533–541CrossRef
11.
von Elm E, Altman D, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, S. Initiative (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344–349CrossRef
12.
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090–1098.CrossRef
13.
Ostwal V, Sahu A, Ramaswamy A, Sirohi B, Bose S, Talreja V, Goel M, Patkar S, Desouza A, Shrikhande SV (2017) Perioperative epirubicin, oxaliplatin, and capecitabine chemotherapy in locally advanced gastric cancer: safety and feasibility in an interim survival analysis. J Gastric Cancer 17(1):21–32CrossRef
14.
Cats A, Jansen E, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH (2018) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 19(5):616–628CrossRef
15.
16.
17.
18.
Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, Hammerlid E, Bottomley A, Van Cutsem E, Blazeby JM, E.O.f.R.T.o.C.G.a.Q.o.L. Groups (2007) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer 43(14):2066–2073CrossRef
19.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRef
20.
Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 Scoring Manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels
21.
22.
Low DE et al (2015) International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). Ann Surg 262(2):286–294CrossRef
23.
24.
Brooks JA, Kesler K, Johnson CS, Ciaccia D, Brown JW (2002) Prospective analysis of quality of life after surgical resection for esophageal cancer: preliminary results. J Surg Oncol 81:185–194CrossRef
25.
Zieren H, Jacobi CA, Zieren J, Muller JM (1996) Quality of life following resection of oesophageal carcinoma. Br J Surg 83:1772–1775CrossRef
26.
Schumacher G, Schmidt S, Schlechtweg N, Roesch T, Sacchi M, von Dossow V, Chopra SS, Pratschke J, Zhukova J, Stieler J, Thuss-Patience P, Neuhaus P (2009) Surgical results of patients after esophageal resection or extended gastrectomy for cancer of the esophagogastric junction. Dis Esophagus 22(5):422–426CrossRef
27.
Lohani KR, Nandipati K, Rollins SE, Fetten K, Lee TH, Pallati PK, Yamamoto SR, Mittal SK (2015) Transthoracic approach is associated with increased incidence of atrial fibrillation after esophageal resection. Surg Endosc 29(7):2039–2045CrossRef
28.
Brinkmann S, Schroeder W, Junggeburth K, Gutschow CA, Bludau M, Hoelscher AH, Leers JM (2016) Incidence and management of chylothorax after Ivor Lewis esophagectomy for cancer of the esophagus. J Thorac Cardiovasc Surg 1(5):1398–1404CrossRef
29.
Fransen L, Berkelmans G, Asti E, Van Berge Henegouwen M, Berlth F, Bonavina L, Brown A, Bruns C, Gisbertz S, Grimminger P, Gutschow C, Hölscher A, Kauppi J, Lagarde SM, Mercer S, Moons J, Nafteux P, Nilsson M, Palazzo F, Pattyn P (2018) FA01.02: The effect of postoperative complications after mie on long-term survival: a retrospective, multi-center cohort study. Dis Esophagus 31(13):1CrossRef
30.
Straatman J, van der Wielen N, Cuesta MA, Daams F, Roig Garcia J, Bonavina L, Rosman C, van Berge Henegouwen MI, Gisbertz SS, van der Peet DL (2017) Minimally invasive versus open esophageal resection: three-year follow-up of the previously reported randomized controlled trial: the TIME trial. Ann Surg 266(2):232–236CrossRef
31.
Al-Batran SE et al (2017) The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction—a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 17(1):893CrossRef
32.
Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch ORC, Coene PPLO, Coupé VMH, Dekker JWT, van Eijck CHJ, Elferink MAG, Erdkamp FLG, van Grevenstein WMU (2018) Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Acta Oncol 57(2):195–202CrossRef
Metadata
Title
Long-Term Quality of Life After Total Gastrectomy Versus Ivor Lewis Esophagectomy
Authors
E. Jezerskyte
L. M. Saadeh
E. R. C. Hagens
M. A. G. Sprangers
L. Noteboom
H. W. M. van Laarhoven
W. J. Eshuis
M. I. van Berge Henegouwen
S. S. Gisbertz
Publication date
01-03-2020
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 3/2020
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-019-05281-8

Other articles of this Issue 3/2020

World Journal of Surgery 3/2020 Go to the issue

Original Scientific Report

Development of a Visual Analytics Tool for Polytrauma Patients: Proof of Concept for a New Assessment Tool Using a Multiple Layer Sankey Diagram in a Single-Center Database

Original Scientific Report

Long-Term and Oncologic Outcomes of Robotic Versus Laparoscopic Liver Resection for Metastatic Colorectal Cancer: A Multicenter, Propensity Score Matching Analysis

Letter to the Editor

Letter to the Editor: Optimal Resources for Children's Surgical Care: Executive Summary

Original Scientific Report

Delay in Source Control in Perforated Peptic Ulcer Leads to 6% Increased Risk of Death Per Hour: A Nationwide Cohort Study

Original Scientific Report

Emergency Department Versus Operating Suite Intubation in Operative Trauma Patients: Does Location Matter?

Invited Commentary

“Hors Tour” Liver Grafts: A Step Towards Optimal Donor and Recipient Matching?